Ben Parkhurst

Ben Parkhurst joined Flagship Pioneering in 2022 as CMC Team Lead for Pioneering Medicines. He is responsible for developing multiple emerging modality medicines and building the subsequent CMC strategies. He works with Flagship companies and external collaborators to expedite the drug development of cutting-edge treatments in Pioneering Medicine’s portfolio.

Ben has more than 11 years of experience working with complex modalities, with over eight years developing viral and non-viral gene therapies. Most recently, he was the Director of Manufacturing Sciences & Technology at Generation Bio where he led a team responsible for the development and manufacturing of ceDNA (closed ended DNA) formulated in LNPs. Previously, Ben supported the build-out of uniQure’s GMP facility and clinical readiness of multiple AAV products. Earlier in his career, he worked on multiple projects at Sanofi, Allergan, and Cubist Pharmaceuticals.

Ben received a master’s degree in Bioengineering from Tufts University and a bachelor’s degree in Biomedical Engineering from Worcester Polytechnic Institute.